> Details

Schmidt, Kira; Krawutschke, Marvin; Kowalski, Axel; Pasche, Saskia; Bialek, Anna; Schweig, Theresa; Weismüller, Benjamin; Tewes, Mitra; Schuler, Martin; Hamacher, Rainer; Müller, Bernhard W.; Schadendorf, Dirk; Skoda, Eva-Maria; Teufel, Martin; Fink, Madeleine

Cancer Patients’ Age-Related Benefits from Mobile Neurofeedback-Therapy in Quality of Life and Self-efficacy: A Clinical Waitlist Control Study

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: Cancer Patients’ Age-Related Benefits from Mobile Neurofeedback-Therapy in Quality of Life and Self-efficacy: A Clinical Waitlist Control Study
  • Contributor: Schmidt, Kira; Krawutschke, Marvin; Kowalski, Axel; Pasche, Saskia; Bialek, Anna; Schweig, Theresa; Weismüller, Benjamin; Tewes, Mitra; Schuler, Martin; Hamacher, Rainer; Müller, Bernhard W.; Schadendorf, Dirk; Skoda, Eva-Maria; Teufel, Martin; Fink, Madeleine
  • imprint: Springer Science and Business Media LLC, 2023
  • Published in: Applied Psychophysiology and Biofeedback
  • Language: English
  • DOI: 10.1007/s10484-022-09571-1
  • ISSN: 1090-0586; 1573-3270
  • Keywords: Applied Psychology ; Neuropsychology and Physiological Psychology
  • Origination:
  • Footnote:
  • Description: <jats:title>Abstract</jats:title><jats:p>Electroencephalographic neurofeedback (EEG NF) can improve quality of life (QoL) and reduce distress by modifying the amplitude of selected brain frequencies. This study aims to investigate the effects of NF therapy on QoL and self-efficacy in cancer patients and to explore age-related reactions. In a waitlist control paradigm, psychometric data (<jats:italic>EORTC QLQ-C30, General Self-Efficacy Scale</jats:italic>) of 20 patients were collected at three different time points, each five weeks apart. An outpatient 10-session NF intervention (mobile) was conducted between the second and third measurement point. QoL and self-efficacy changed significantly over time (QoL: <jats:italic>F</jats:italic>(2,36) = 5.294, <jats:italic>p</jats:italic> &lt; .05, <jats:italic>η</jats:italic><jats:sup>2</jats:sup> = .227; Self-efficacy: <jats:italic>F</jats:italic>(2,26) = 8.178, <jats:italic>p</jats:italic> &lt; .05, <jats:italic>η</jats:italic><jats:sup>2</jats:sup> = .386). While QoL increased in younger patients, older patients initially showed a decrease in QoL, which then increased during intervention. Younger patients did not differ from older patients in QoL in both waitlist control (T0-T1) and intervention phase (T1–T2). QoL in older patients significantly differed between waitlist control and intervention phase (<jats:italic>Z</jats:italic> = − 2.023, <jats:italic>p</jats:italic> &lt; .05, <jats:italic>d</jats:italic> = 1.085). Self-efficacy increased in both age categories. Younger and older patients did not differ in self-efficacy in waitlist control, but in intervention phase (<jats:italic>F</jats:italic>(1,16) = 7.014, <jats:italic>p</jats:italic> &lt; .05, <jats:italic>η</jats:italic><jats:sup>2</jats:sup> = .319). The current findings suggest that NF therapy is a promising treatment modality for improving QoL in cancer patients. Our study reveals NF being a tool to influence self-efficacy, which should receive more appreciation in clinical care. However, the effect of NF in different age groups as well as the influence on further cancer-related symptoms should be investigated in future research. </jats:p>